Ocugen Licenses OCU400 Gene Therapy to Roots Pharma for MENA, Up to $259M in Milestones
OCGN is trading near its 52-week low of $0.87 (5.7% above the low).
Summary
Ocugen signed a licensing deal with Roots Pharmaceutical for exclusive MENA rights to OCU400, its gene therapy for retinitis pigmentosa. Ocugen gets an upfront fee plus up to $4M in development milestones, up to $255M in sales milestones, and a 22% royalty on net sales. The deal also includes a supply agreement for commercial manufacturing. This expands OCU400's reach into a region where RP prevalence is estimated 10-20x higher than the US/EU. The agreement follows recent regulatory progress in The Bahamas and comes as Ocugen advances the Phase 3 liMeliGhT trial with topline data expected in Q1 2027. Ocugen postponed its special meeting on increasing authorized shares by 250,000,000 to December 22, 2026, with a new record date of October 30, 2026.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Ocugen postponed its special meeting on increasing authorized shares by 250,000,000 to December 22, 2026, with a new record date of October 30, 2026.
At the time of this announcement, OCGN was trading at $0.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $300.2M. The 52-week trading range was $0.87 to $2.73. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.